Sun Pharma gets USFDA nod for Ximino
Sun Pharmaceuticals has received the US Food and Drug Administration's (USFDA) approval for its supplemental new drug application for Ximino, an extended release capsule. This would strengthen Sun's branded dermatology portfolio in the US market.
August 19, 2015: The firm has been building on its dermatology segment and has plans to make it its biggest revenue segment and expects that 40 per cent of US sales to come from dermatology by FY18. Sun expects Ximino which is used for treating acne vulgaris, to be available for patients during the December quarter.